Toronto, Canada
Ostia Sciences Inc., founded in 2020, is an innovative company operating in the intersection of Biopharma, Biotechnology, and Health Care. Based in Canada, it focuses on developing Microbiome-Derived Biotherapeutics to harness the potential of the human microbiome.
The company specializes in discovering novel bacterial metabolites that exhibit antibacterial, antibiofilm, and immunomodulation activities. By isolating beneficial microbes from sources such as the human oral microbiome, human breast milk, and fermented food, Ostia Sciences Inc. aims to develop therapeutics with a broad range of biological activities, drawing on rich sources of ribosomally synthesized and post-translationally modified peptides (RiPPs).
Notably, the company has yet to secure its latest investment, presenting a potential opportunity for venture capitalists interested in pioneering microbiome technologies with promising therapeutic applications.
